Blood Podcast Summary – April 17, 2025 Episode

Hosted by the American Society of Hematology, the April 17, 2025 episode of the Blood Podcast delves into three pivotal studies recently published in Blood, the leading peer-reviewed journal in hematology. The episode explores the evolving role of autologous transplants in relapsed multiple myeloma, the efficacy of DDAVP in bleeding disorders, and innovative dual-targeting strategies in diffuse large B-cell lymphoma (DLBCL).

1. The Decline of Transplant for Relapsed Myeloma

Overview: The podcast opens with a discussion on the long-term follow-up of the Phase 3 GMMG relapse trial, led by first author Marc Andrea Bartsch from the Heidelberg Myeloma Center in Germany. This study critically examines the survival benefits of salvage autologous transplant in relapsed or refractory multiple myeloma patients who have previously undergone frontline high-dose chemotherapy and autologous stem cell transplantation.

Key Findings:

• Survival Outcomes: After a median follow-up of over eight years, the study revealed no significant difference in progression-free survival (PFS) or overall survival (OS) between patients undergoing salvage transplant and those receiving control chemotherapy (Bartsch, 15:30).

  • "With no significant PFS or OS benefit compared to LenDex," notes Aurora Perrault, author of the accompanying commentary (25:45).

• Clinical Implications: These findings challenge existing guidelines that advocate for salvage transplants, particularly in patients with a long time to progression post-frontline transplant. The emergence of alternative treatments like triplet regimens and CAR T-cell therapies further diminishes the perceived benefits of salvage transplants.

• Limitations: The high dropout rate of 29% before salvage therapy and the use of potentially suboptimal control therapies (e.g., LenDex doublet prior to transplant) are acknowledged as limitations that may affect the interpretation of results.

Conclusion: Perrault emphasizes the study's impact by stating, "The lack of survival benefit raises questions about the routine use of salvage transplantation, especially when highly effective alternatives are available" (25:45). The study suggests a reevaluation of salvage transplant practices, weighing the quality of life and toxicity against newer, less invasive treatment options.

2. DDAVP Response in Bleeding Disorders

Overview: The second segment explores a groundbreaking meta-analysis by Sebastian Lan and colleagues from Erasmus University Medical Center. This study is the first large-scale assessment of DDAVP (desmopressin) response rates across various bleeding disorders, shedding light on factors influencing patient responses.

Key Findings:

• Response Rates:

  • The pooled response proportion was 71% overall.
  • Complete response rates were highest in VWD Type 1 (89%) and VWD Type 2 (83%), but significantly lower in Hemophilia A (HA) patients (10%) (Lan et al., 40:20).

• Determinants of Response:

  • Disease Subtype: VWD Type 1 showed the highest responsiveness to DDAVP.
  • Baseline Factor Levels: Higher baseline levels of von Willebrand factor (VWF) and factor VIII coagulant activity were associated with better responses.
  • Age and Weight: Trends indicated that older age and higher weight may correlate with increased response rates.
  • Genetic Mutations: Responses varied even among patients with identical mutations in factor VIII and VWF genes, highlighting heterogeneity.

Notable Insight: Lan explains, "These differences in DDAVP response emphasize the need for a standardized response definition and further research into response mechanisms" (58:10).

Clinical Implications:

• The high response rates in VWD Type 1 support current guidelines advocating for DDAVP testing in these patients.
• In contrast, the low response rates in HA patients suggest that DDAVP testing is crucial to determine suitability before resorting to more expensive and invasive treatments.

Conclusion: The study underscores the necessity of individualized DDAVP testing in heterogeneous bleeding disorders to optimize treatment strategies and avoid unnecessary interventions.

3. Dual DOT1L/EZH2 Targeting in Diffuse Large B-Cell Lymphoma (DLBCL)

Overview: The final discussion centers on innovative research by Camille Goebel and team from the Netherlands Cancer Institute. Their study investigates the combined inhibition of DOT1L and EZH2 enzymes as a therapeutic strategy in germinal center B-cell (GCB) subtype of DLBCL.

Key Findings:

• Mechanism of Action:

  • GCB DLBCL relies on DOT1L and EZH2 to maintain a pro-proliferative identity.
  • Dual inhibition disrupts this identity, inducing a "cell identity crisis" that promotes differentiation toward a plasma cell-like state, ultimately compromising cell survival (Goebel et al., 72:05).

• Preclinical Results:

  • In Vitro: The combination therapy exhibited synergistic activity, significantly reducing proliferation in GCB DLBCL cell lines.
  • In Vivo: In mouse xenograft models, the dual treatment effectively prevented tumor growth with manageable toxicity profiles, primarily nephrotoxicity and reduced erythropoiesis (72:50).

Notable Insight: Jerome Moreau, in his commentary, highlights the novelty of the approach by stating, "This new work should prompt clinical evaluation of the synergistic potential of this combination" (94:30).

Clinical Implications:

• The dual-targeting strategy presents a promising alternative for treating DLBCL, especially in cases refractory to standard R-CHOP chemoimmunotherapy.
• Given the significant subset of patients with MYC-translocated DLBCL, this approach offers hope for improved outcomes in aggressive and poor-prognosis cases.

Conclusion: The study by Goebel et al. provides a compelling foundation for advancing dual DOT1L/EZH2 inhibition into clinical trials, potentially revolutionizing treatment paradigms for DLBCL.

Closing Remarks: The Blood Podcast effectively synthesizes complex hematological research, offering listeners insightful analyses and expert commentaries. For more detailed information on these studies, visit bloodjournal.org and refer to the show notes of this episode.

You have been listening to the Blood Podcast. Join us next week for another episode of cutting-edge hematology insights.